RARE ULTRAGENYX PHARMACEUTICAL INC Product Launches 8-K Filing 2024 - Phase 2/3 Orbit Study Results Ultragenyx Pharmaceutical Inc. announced positive 14-month results from the Phase 2 portion of the ongoing Phase 2/3 Orbit study, demonstrating significant reduction in fractures and improvements in bone mineral density in patients with osteogenesis imperfecta.Get access to all SEC 8-K filings of the ULTRAGENYX PHARMACEUTICAL INC